Share on StockTwits

Alimera Sciences (NASDAQ:ALIM) SVP David Holland unloaded 5,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $6.02, for a total value of $30,100.00. Following the completion of the sale, the senior vice president now directly owns 98,362 shares in the company, valued at approximately $592,139. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alimera Sciences (NASDAQ:ALIM) traded up 2.02% on Thursday, hitting $6.07. The stock had a trading volume of 20,801 shares. Alimera Sciences has a 52-week low of $1.65 and a 52-week high of $8.44. The stock has a 50-day moving average of $5.66 and a 200-day moving average of $6.00. The company’s market cap is $244.8 million.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.05. The company had revenue of $2.08 million for the quarter, compared to the consensus estimate of $1.15 million. During the same quarter in the prior year, the company posted ($0.27) earnings per share. Analysts expect that Alimera Sciences will post $-1.19 EPS for the current fiscal year.

Alimera Sciences, Inc is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.